Aclarion gets $2M debt financing
- Healthcare technology company, Aclarion (NASDAQ:ACON) closes of up to a $2M unsecured, non-convertible debt financing that allows the company to continue executing its 2023 plan.
- The financing will support execution of the 2023 plan and the achievement of critical milestones in support of definitive growth capital.
- The company recently announced publication of two year follow up data on its foundational clinical trial demonstrating improved surgical results for patients undergoing surgery at the discs Nociscan identified as pain generators.